$OMC: Omnicom Group Reports Fourth Quarter and Full Year 2018 Results

Date: Tuesday, February 12th, 2019

Stock(s) mentioned:

Source: PRNewswire (https://www.prnewswire.com)

Summary: 12, 2019 /PRNewswire/ — Omnicom Group Inc. (NYSE: OMC) today announced that its net income for the fourth quarter of 2018 increased $144.8 million, …

Full article address: https://www.prnewswire.com/news-releases/omnicom-group-reports-fourth-quarter-and-full-year-2018-results-300793946.html

Related News:

$UBER $LYFT $ED $OMC $TWTR: Do the economics of ride-hailing make any sense?

$OMC: Why Is Omnicom (OMC) Down 5.6% Since Last Earnings Report?

$OMC: Options Bulls May Want to Bet On This Underloved Stock

$OMC: ICON International’s Local Group Hires Jane Meyerson

$OMC: DDB Worldwide Named Network of the Year at The One Show

$OMC: Merida Capital Adds Former Omnicom Group and Medco Health …

$OMC: Ketchum Wins Five North America SABRE Awards

$OMC: ICON International has Opened an Office in Fort Lauderdale

$OMC: Ad giants rise after Interpublic’s beat

$OMC: Surf’s Up At TBWA\Chiat\Day Los Angeles In 2019

$OMC: The Marketing Arm Connected Top NFL Prospects & Brands in the …

Latest News:

$SPY $BABA: If a popular options strategy suddenly implodes, be ready to scoop up cheap blue chips

$GE: Is General Electric a Buy?

$HD $URBN: Home Depot, Target, HP, Best Buy and More Major Earnings …

$TMUS: Masayoshi Son: Genius or insane? Maybe neither

$DAL $ALK $LUV $NFLX $UAL: Delta’s test of free in-flight Wi-Fi may shame other airlines into offering service

$AVTR $FSLY $LK $LYFT $PINS $UBER: Why the IPO Boom Will Continue

$SBUX: Millions of Americans Could Miss Work Tomorrow After the ‘Game of Thrones’ Finale

$AMZN $OXY $APC $WFC $SRE: Want to invest like Warren Buffett? Here are the ins and outs of buying preferred stock

$TSLA $GM: Tesla fires could dampen electric car sales as industry ramps up EV production, auto analysts say

$ROKU $GH $CVNA: 3 Stocks That Have Doubled in 2019 — Are They Still Buys?

$AXSM: Here’s Why You’ll Regret Ignoring This Biotech Stock Rocket